Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-02
2005-08-02
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S369000, C548S183000, C548S226000, C548S227000, C548S369400
Reexamination Certificate
active
06924301
ABSTRACT:
A composition for treating or preventing arrhythmia containing as an active ingredient a cPLA2inhibitor, for example a compound represented by formula (I):wherein R1is optionally substituted aralkyl or the like; Z is —S— or the like; X1is —(CH2)s-N(R18)—CO— (wherein R18is hydrogen atom or the like, s is an integer of 0 to 3) or the like; X2is optionally substituted arylene or the like; X3is a bond or the like; A, B, and E are each independently oxygen atom or sulfur atom; D is hydrogen atom or the like; Y1is —(CH2)mCO— (m is an integer of 0 to 3) or the like; Y2is optionally substituted aryl or the like.
REFERENCES:
patent: 5208244 (1993-05-01), Weiss et al.
patent: 5434288 (1995-07-01), Lennon et al.
patent: 5955616 (1999-09-01), Ohtani et al.
patent: 6147100 (2000-11-01), Seno et al.
patent: 0 544 488 (1993-06-01), None
patent: 0 848 004 (1998-06-01), None
patent: 0 976 748 (2000-02-01), None
patent: 9-110835 (1997-04-01), None
patent: 09-110835 (1997-04-01), None
patent: 09-268153 (1997-10-01), None
patent: WO 97/05135 (1997-02-01), None
patent: WO 98/08818 (1998-03-01), None
patent: WO 98/33797 (1998-08-01), None
Dewindt, et al., “Phospholipase A2-mediated hydrolysis of cardiac phospholipids: The use of molecular and transgenic techniques”,Molecular and Cellular Biochemistry, 180: 65-73, (1998), Kluwer Academic Publishers, The Netherlands.
Fazekas, et al., “Effect of Chloroquine in Experimental Myocardial Ischaemia”,Acta Physiologica Hungarica, pp. 191-199, vol. 72 (2), (1988), Akadémiai Kiadó, Budapest.
Filippov, et al., “Ca2+-Antagonistic Properties of Phospholipase A2Inhibitors, Mepacrine and Chloroquine”,Gen. Physiol. Biophys., 8, 113-118 (1989), 14292 Poshchino, Moscow Region, USSR.
Shaikh, et al., “Amiodarone—an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine”,Molecular and Cellular Biochemistry 76: 163-172 (1987), Martinus Nijhoff Publishers, Boston—Printed in The Netherlands.
Dole et al., “Microdetermination of Long-chain Fatty Acids in Plasma and Tissues,”The Journal of Biological Chemistry, Sep. 1990, pp. 2595-2599, vol. 235, No. 9.
Kramer et al., “The Ca2+-sensitive Cytosolic Phospholipase A2Is a 100-kDa Protein in Human Monoblast U937 Cells,”The Journal of Biological Chemistry, Mar. 15, 1991, pp. 5268-5272, vol. 266, No. 8.
Manning et al., “Ischemia and Reperfusion-Induced Arrhythmaias in the Rat,”Circulation Research, Oct. 1984, pp. 545-548, vol. 55, No. 4.
Sedlis et al., “Time course of lysophosphatidylcholine release from ischemic human myocardium parallels the time course of early ischemic ventricular arrhythmia,”Coronary Artery Disease, Jan. 1997, pp. 19-27, vol. 8, No. 1.
Murakami et al., “Functional Coupling Between Various Phospholipase A2s and Cyclooxygenases in Immediate and Delayed Prostanoid Biosynthetic Pathways,”The Journal of Biological Chemistry, Jan. 29, 1999, pp. 3103-3115, vol. 274, No. 5.
Hori Yozo
Seno Kaoru
Foley & Lardner LLP
Jones Dwayne
Shionogi & Co. Ltd.
LandOfFree
Composition for treating or preventing arrhythmia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for treating or preventing arrhythmia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for treating or preventing arrhythmia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3500348